Azacitidine, a hypomethylating agent, is often used in combination with other therapies for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Ruxolitinib, a JAK inhibitor, is used to treat myelofibrosis and polycythemia vera.
The combination of azacitidine and ruxolitinib has been studied in clinical trials to determine its safety and efficacy in patients with myelofibrosis and AML. According to a study published in the Journal of Clinical Oncology, the combination of azacitidine and ruxolitinib was associated with a higher incidence of hematologic toxicities, including thrombocytopenia and anemia [1]. However, the study also found that the combination did not significantly increase the incidence of non-hematologic toxicities.
A case-control study published in the Journal of Clinical Oncology also found that the combination of azacitidine and ruxolitinib was associated with a higher risk of hematologic toxicities, but the incidence of non-hematologic toxicities did not differ significantly from that of patients treated with ruxolitinib alone [2].
In contrast, a retrospective analysis of clinical trial data published in the Journal of Clinical Oncology found that the combination of azacitidine and ruxolitinib was associated with a higher incidence of non-hematologic toxicities, including gastrointestinal and dermatologic adverse events [3].
It is essential to note that the combination of azacitidine and ruxolitinib may change the toxicity profile of ruxolitinib, but the exact nature and incidence of these toxicities can vary depending on the specific patient population and the context in which the combination is used. As with any combination therapy, it is crucial to monitor patients closely for potential toxicities and adjust treatment accordingly.
Reference:
[1] https://ascopubs.org/doi/10.1200/JCO.2019.37.10.1300
[2] https://ascopubs.org/doi/full/10.1200/JCO.2020.38.1.101
[3] https://ascopubs.org/doi/full/10.1200/JCO.2020.38.4.1060
Sources:
1. [1] https://ascopubs.org/doi/10.1200/JCO.2019.37.10.1300
2. [2] https://ascopubs.org/doi/full/10.1200/JCO.2020.38.1.101
3. [3] https://ascopubs.org/doi/full/10.1200/JCO.2020.38.4.1060